136 patents
Utility
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds And/or Formulations
14 Dec 23
Lu Chou, Matt Duan, Ihab S. Darwish, Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor, Yan Chen, Dazhong Fan, Zhushou Luo
Filed: 24 Aug 23
Utility
Bicyclic Inhibitors of Irak
7 Dec 23
Yan Chen, Esteban Masuda, Chrystelle Lamagna
Filed: 31 May 23
Utility
Compositions and methods for inhibition of the JAK pathway
28 Nov 23
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
Filed: 2 Nov 21
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
12 Oct 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Somasekhar BHAMIDIPATI, Vanessa TAYLOR
Filed: 14 Jun 23
Utility
Tricyclic Irak Inhibitors
5 Oct 23
Zhushou Luo, Simon Shaw, Ihab Darwish, Estaban Masuda, Chrystelle Lamagna
Filed: 30 Mar 23
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
5 Oct 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Jiaxin YU, Ihab DARWISH, Vanessa TAYLOR, Rao KOLLURI, Yan CHEN, Simon SHAW, Somasekhar BHAMIDIPATI, Zhushou LUO
Filed: 6 Dec 22
Utility
PYRIMID-2-YL-PYRAZOLE Compounds As Irak Inhibitors
28 Sep 23
Jack Maung, Yan Chen, Simon Shaw, David Sweeny, Esteban Masuda
Filed: 22 Mar 23
Utility
RIP1K Inhibitors
20 Jul 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Ihab DARWISH, Zhushou LUO, Vanessa TAYLOR
Filed: 13 Jan 23
Utility
Heterocyclic RIP1 Inhibitory Compounds
11 May 23
Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
Filed: 16 Dec 22
Utility
TGF-SS Inhibitors
20 Apr 23
Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
Filed: 7 Oct 22
Utility
Amide Compounds and Method for Making and Using
13 Apr 23
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
Filed: 9 Nov 22
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
13 Apr 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
Filed: 17 Jun 22
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
13 Apr 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban MASUDA, Simon SHAW, Vanessa TAYLOR, Somasekhar BHAMIDIPATI
Filed: 7 Sep 22
Utility
2,4-DIAMINO-PYRIMIDINE Compounds and Method for Making and Using the Compounds
30 Mar 23
Yan Chen, Rose Yen, Jiaxin Yu, Vanessa Taylor, Rajinder Singh
Filed: 16 Nov 22
Utility
Irak Inhibitors and Method for Making and Using
2 Mar 23
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors.
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Filed: 27 Sep 22
Utility
Heterocyclic RIP1 Kinase Inhibitors
23 Feb 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Simon SHAW, Somasekhar BHAMIDIPATI, Vanessa TAYLOR
Filed: 16 Sep 22
Utility
RIP1K inhibitors
21 Feb 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Ihab Darwish, Zhushou Luo, Vanessa Taylor
Filed: 2 Apr 21
Utility
Heterocyclic RIP1 inhibitory compounds
14 Feb 23
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 6 Nov 20
Utility
RIP1 inhibitory compounds and methods for making and using the same
31 Jan 23
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
Filed: 4 Sep 20
Utility
Tyrosine Kinase Inhibitors
19 Jan 23
Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
Filed: 2 Sep 21